Skip to content

Cro services in

Lung (IPF)

Accelerate your drug development by exploring clinical pulmonary function endpoints and histopathological readouts in our BLEO-IPF mouse models. We apply clinically relevant endpoints to ensure model translatability and the understanding of drug mode-of-action.

Why Gubra?
  • In-depth validated mouse models of IPF
  • Spirometry-confirmed lung dysfunction
  • Whole body plethysmography-validated disease stratification at baseline
  • Automated AI-based histopathological scoring
  • Profile compounds using clinical trial endpoints
  • Tailored study design and rapid initiation

Consult with Michael Feigh

Vice President, Scientific Sales

Reach out to our experts to learn how we can move your IPF drug pipeline forward

Advance your study in
spirometry-confirmed IPF models

We offer bleomycin-induced IPF mouse models with hallmarks of lung dysfunction confirmed by spirometry and whole body plethysmography. Our advanced study design allows for therapeutic intervention assessing anti-fibrotic efficacy.

Main Offerings

Lung function testing
Spirometry & Whole body plethysmography

Biochemical assessment
Plasma, Lung & BALF

Ashcroft scoring

Quantitative histology
Inflammation & fibrosis

Lung transcriptomic profile

advanced bleomycin models

Idiopathic Pulmonary Fibrosis (IPF) Models

Related pages

For further information

Contact us


Hørsholm Kongevej 11B
2970 Hørsholm

+45 3152 ­2650

Back To Top